On November 17, CRISPR Therapeutics AG fell 5.2% in Regular Trading, trading at $40.045 per share, with turnover of $47.3887 million.
The latest identifiable catalyst was an event-driven update: an analyst reiterated a Buy rating and set an $80 price target, but the move did not provide visible support for the shares, with trading still reflecting caution around the pace of commercialization and early-pipeline execution.
Recent company updates show mixed fundamentals and pipeline momentum. The company reported quarterly EPS of $(1.15), missing the $(0.98) consensus estimate, while revenue of $12.669 million beat the $10.495 million estimate. Separately, Casgevy use was described as continuing to grow, and earlier Phase 1b data for CTX310 showed average ANGPTL3 reduction of 65% and triglyceride reduction of 63%, alongside early positive autoimmune data for zugo-cel.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments